肝硬化患者血小板胞内Ca2+浓度、CD62P、CD63及血浆CD62P的检测

l摘fi 目的 探讨肝硬化患者与血小板a一颗粒膜蛋白(CD。。P)、血小板糖蛋白(CD。。)、血浆CD。f(SCD。I)水平及血小板Ca’‘＊的关系。方法 利用流式细胞术检测血小板 CD。。P、CD。。,酶联免疫吸附法测定SCD。f和荧光分光光度法测定血小板Ca‘”h。结果 肝硬化患者血小板Ca’”]i、CD。。P、CD。。、SCD。;P分别为(103.l士 22.2)nmol/L、(47.6上 20.0)％、(47.1士 24.6)％和(67.6士 37.6)no/L,对照组分别为(57.6 t13.l)nmol/L、(3.h 0,7)％、(2.510.7)％和(24.016.5)ug/L,两组比较差异有显著性,t值为6.148—19.067,P<0.05;上消化道出血组分别为(120.3 i 18.8)urn。l/L、(64.9 i 14.7)％、(7.9 i 14二5)％和(103.6士 14.9)ug/L,无出血组分别为(91.l士 14.3)nmol/L、(3.6士 11.9)％、(30.2士 14.4)％和(40.8 i 24.0)u0.05)。结论 肝硬化患者血小板高度活化,检测血小板CD62P、CD63、SCD62P对判断肝硬化的严重程度有一定参考价值。

Detection of platelet Ca2+i, CD62P, CD63 and plasma CD62P in cirrhosis patients

OBJECTIVES: To study on the relationship between platelet Ca2+(i), CD62P, CD63, serum CD62P (SCD62P) and cirrhosis patients. METHODS: Platelet CD62P, CD63 were determined with flow cytometry, SCD63P with ELISA, and Ca2+(i) in platelet was determined with fluorophotometry. RESULTS: Platelet Ca2+(i), CD62P, CD63, and SCD62P levels in cirrhosis patients were (103.1+/-22.2)nmol/L, (47.6+/-20.0)%, (47.1+/-24.6)%, and (67.6+/-37.6)microg/L, and in controls were (57.6+/-13.1)nmol/L, (3.1+/-0.7)%, (2.5+/-0.7)%, and (24.0+/-6.5)microg/L, respectively. The levels in the former were higher than those in the latter (t > or = 6.148, P<0.05). The above levels in upper gastrointestinal haemorrhage group were much higher than those in the non-haemorrhage group (120.3nmol/L+/-18.8nmol/L vs 91.1nmol/L+/-14.3nmol/L, 64.9%+/-14.7% vs 34.6%+/- 11.9%, 70.9%+/-14.5% vs 30.2%+/-14.4%, and 103.6microg/L+/-14.9microg/L vs 40.8microg/L+/-24.0microg/L, respectively, t > or = 5.380, P<0.05). But the numbers of platelet between the two groups were no obvious difference. CONCLUSIONS: Platelet in the cirrhosis patients is greatly active, and the detection of platelet CD62P, CD63, SCD62P has a certain value in judging the degree of cirrhosis.